BR112016013734A2 - Composto, composição farmacêutica, kit, e uso de um composto - Google Patents

Composto, composição farmacêutica, kit, e uso de um composto

Info

Publication number
BR112016013734A2
BR112016013734A2 BR112016013734A BR112016013734A BR112016013734A2 BR 112016013734 A2 BR112016013734 A2 BR 112016013734A2 BR 112016013734 A BR112016013734 A BR 112016013734A BR 112016013734 A BR112016013734 A BR 112016013734A BR 112016013734 A2 BR112016013734 A2 BR 112016013734A2
Authority
BR
Brazil
Prior art keywords
compound
compounds
kit
pharmaceutical composition
methods
Prior art date
Application number
BR112016013734A
Other languages
English (en)
Inventor
Thompson Scott
Venkatesan Aranapakam
Priestley Tony
KUNDU Mrinal
Saha Ashis
Original Assignee
Asana Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences Llc filed Critical Asana Biosciences Llc
Publication of BR112016013734A2 publication Critical patent/BR112016013734A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, KIT, MÉTODOS PARA REGULAR UM OU AMBOS DOS RECEPTORES P2X 3 OU P2X 2/3, PARA TRATAR DOR EM UM PACIENTE, E PARA MODULAR UMA OU AMBAS DAS VIAS P2X 3 OU P2X 2/3. O presente pedido provê compostos e métodos novos para preparar e usar estes compostos. Em uma modalidade, os compostos apresentam a estrutura da fórmula (I), em que R1 -R 4 são aqui definidos. Em uma modalidade adicional, estes compostos são úteis em método para regular um ou ambos dos receptores P2X3 ou P2X2/3. Em uma outra modalidade, estes compostos são úteis para tratar dor em pacientes administrando um ou mais dos compostos a um paciente.
BR112016013734A 2013-12-16 2014-12-16 Composto, composição farmacêutica, kit, e uso de um composto BR112016013734A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361916499P 2013-12-16 2013-12-16
PCT/US2014/070497 WO2015095128A1 (en) 2013-12-16 2014-12-16 P2x3 and/or p2x2/3 compounds and methods

Publications (1)

Publication Number Publication Date
BR112016013734A2 true BR112016013734A2 (pt) 2017-08-08

Family

ID=52347419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013734A BR112016013734A2 (pt) 2013-12-16 2014-12-16 Composto, composição farmacêutica, kit, e uso de um composto

Country Status (11)

Country Link
US (7) US9944637B2 (pt)
EP (1) EP3083619B1 (pt)
JP (2) JP6616772B2 (pt)
KR (2) KR102430072B1 (pt)
CN (1) CN106029660B (pt)
AU (1) AU2014365823B2 (pt)
BR (1) BR112016013734A2 (pt)
CA (1) CA2933811C (pt)
HK (1) HK1226718A1 (pt)
IL (1) IL246191B (pt)
WO (1) WO2015095128A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014365823B2 (en) * 2013-12-16 2019-05-02 Abs Development 1, Inc. P2X3 and/or P2X2/3 compounds and methods
EP3528813A4 (en) 2016-09-30 2020-06-03 Asana BioSciences, LLC P2X3 AND / OR P2X2 / 3 CONNECTIONS AND METHOD
US20210267203A1 (en) 2018-06-29 2021-09-02 Syngenta Participations Ag Pesticidally active azole-amide compounds
TW202019901A (zh) 2018-09-13 2020-06-01 瑞士商先正達合夥公司 殺有害生物活性唑-醯胺化合物
UY38367A (es) 2018-09-13 2020-04-30 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
CN112888680A (zh) 2018-10-19 2021-06-01 先正达参股股份有限公司 杀有害生物活性的唑-酰胺化合物
JP2022509019A (ja) 2018-11-05 2022-01-20 シンジェンタ パーティシペーションズ アーゲー 殺有害生物的に活性なアゾール－アミド化合物
CN111253402B (zh) * 2018-11-30 2021-08-03 广州白云山医药集团股份有限公司白云山制药总厂 一种trk激酶抑制剂化合物的中间体化合物及制备方法
EP3696175A1 (en) 2019-02-18 2020-08-19 Syngenta Crop Protection AG Pesticidally active azole-amide compounds
JP2022523434A (ja) 2019-03-08 2022-04-22 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性なアゾール－アミド化合物
WO2020188014A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
WO2020188027A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
JP2022525809A (ja) 2019-03-22 2022-05-19 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺虫剤としてのｎ－［１－（５－ブロモ－２－ピリミジン－２－イル－１，２，４－トリアゾール－３－イル）エチル］－２－シクロプロピル－６－（トリフルオロメチル）ピリジン－４－カルボキサミド誘導体及び関連化合物
WO2021016317A1 (en) * 2019-07-23 2021-01-28 Constellation Pharmaceuticals, Inc. Modulators of trex1
CN111892585A (zh) * 2020-08-05 2020-11-06 杭州维坦医药科技有限公司 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2962463D1 (en) 1978-11-27 1982-05-19 Bruno Granella Mobile tearing-up apparatus for treating a ground surface
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5633002A (en) 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5411738A (en) 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US5266325A (en) 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
JP3471122B2 (ja) 1995-04-26 2003-11-25 アルケア株式会社 医療用粘着配合物
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
SE508357C2 (sv) 1996-01-02 1998-09-28 Kay Laserow Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
AU6876498A (en) 1997-04-03 1998-10-22 Point Biomedical Corporation Intravesical drug delivery system
US6623040B1 (en) 1997-09-03 2003-09-23 Recot, Inc. Method for determining forced choice consumer preferences by hedonic testing
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
CN1250171C (zh) 2000-10-13 2006-04-12 阿尔扎公司 利用微凸起刺入皮肤的装置和方法
ATE428466T1 (de) 2000-10-26 2009-05-15 Alza Corp Transdermales arzneistoffverabreichungssytem mit beschichteten mikrovorsprüngen
US6766319B1 (en) 2000-10-31 2004-07-20 Robert J. Might Method and apparatus for gathering and evaluating information
EP1864660B1 (en) 2001-11-01 2010-12-29 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7812303B2 (en) 2007-12-06 2010-10-12 The United States Of America As Represented By The Secretary Of The Army Method and system for creating an image using quantum properties of light based upon spatial information from a second light beam which does not illuminate the subject
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2587780A1 (en) 2004-11-18 2006-05-26 Transpharma Medical Ltd. Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
AR056290A1 (es) 2005-03-31 2007-10-03 Nippon Soda Co Metodo para inhibir la produccion de de micotoxina
JP4850913B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３及びｐ２ｘ２／３調節因子としてのジアミノピリジン
GB0525029D0 (en) 2005-12-08 2006-01-18 Univ Hull Receptor Antagonist
MX2011004570A (es) * 2008-10-31 2011-06-17 Merck Sharp & Dohme Antagonistas del receptor p2x3 para el tratamiento del dolor.
CN102215901B (zh) 2008-11-07 2014-12-03 联合生物医学系统有限公司 用于治疗和/或预防疾病的装置和方法
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
US20110046600A1 (en) 2008-12-05 2011-02-24 Crank Justin M Devices, systems, and related methods for delivery of fluid to tissue
EP2410857B1 (en) * 2009-03-23 2014-01-29 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CA2755768A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
ES2457543T3 (es) 2009-06-22 2014-04-28 F. Hoffmann-La Roche Ag Nuevas arilamidas de indazol como antagonistas de P2X3 y/o P2X2/3
DE102009030377A1 (de) 2009-06-25 2010-12-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Schallabsorber für Fahrzeugräder
AU2014365823B2 (en) * 2013-12-16 2019-05-02 Abs Development 1, Inc. P2X3 and/or P2X2/3 compounds and methods

Also Published As

Publication number Publication date
IL246191B (en) 2021-03-25
KR102430072B1 (ko) 2022-08-10
US10544145B2 (en) 2020-01-28
WO2015095128A1 (en) 2015-06-25
US20180141945A1 (en) 2018-05-24
EP3083619A1 (en) 2016-10-26
JP7182526B2 (ja) 2022-12-02
US20230219954A1 (en) 2023-07-13
KR20220112867A (ko) 2022-08-11
KR20160097250A (ko) 2016-08-17
JP6616772B2 (ja) 2019-12-04
CA2933811A1 (en) 2015-06-25
JP2016540027A (ja) 2016-12-22
AU2014365823A1 (en) 2016-07-07
US9944637B2 (en) 2018-04-17
US9908879B2 (en) 2018-03-06
US10316039B2 (en) 2019-06-11
AU2014365823B2 (en) 2019-05-02
CN106029660B (zh) 2019-11-15
EP3083619B1 (en) 2021-11-03
JP2020007322A (ja) 2020-01-16
US20160296501A1 (en) 2016-10-13
US20160318927A1 (en) 2016-11-03
US11685736B2 (en) 2023-06-27
US20180186793A1 (en) 2018-07-05
CN106029660A (zh) 2016-10-12
US10590127B2 (en) 2020-03-17
US20200109143A1 (en) 2020-04-09
US20190248789A1 (en) 2019-08-15
IL246191A0 (en) 2016-08-02
HK1226718A1 (zh) 2017-10-06
CA2933811C (en) 2021-02-09

Similar Documents

Publication Publication Date Title
BR112016013734A2 (pt) Composto, composição farmacêutica, kit, e uso de um composto
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112019006216A2 (pt) compostos de p2x3 e/ou p2x2/3 e métodos
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
BR112015008487A2 (pt) compostos de benzeno substituído
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112012023021A2 (pt) compostos de indazol e seus usos
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
BR112016005271A2 (pt) Moduladores de canais de sódio para o tratamento da dor e do diabetes
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015023153A2 (pt) utilização de um composto e composto
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112014032581A2 (pt) inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements